Posted by Michael Wonder on 19 Aug 2020
Launch of two biosimilars
19 August 2020 - Sandoz Canada announces an agreement with the pCPA and the launches of Ziextenzo and Riximyo.
Sandoz Canada announces it has reached a negotiated agreement with the Pan-Canadian Pharmaceutical Alliance (pCPA) and launched Ziextenzo (pegfilgrastim, reference biologic drug: Neulasta) and Riximyo (rituximab, reference biologic drug: Rituxan) in Canadian hospitals and pharmacies. This follows the recent approval of the two biosimilars by Health Canada.
Pursuing the pCPA agreement, Riximyo is now reimbursed in Ontario effective July, 2020 through Limited Use as well as Exceptional Access Program for certain indications, and funding in hospitals will be provided by Cancer Care Ontario. In addition, British Columbia has recently announced the reimbursement of Riximyo effective August 1, 2020 through BC Cancer.
